EW
TGTX icon

Evoke Wealth’s TG Therapeutics TGTX Stock Holding History

Evoke Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-219
Closed -$2K – 1248
2022
Q1 		$2K Buy
219
+154
+237% +$1.78K ﹤0.01% 1075
2021
Q4 		$1K Hold
65
– – ﹤0.01% 1150
2021
Q3 		$2K Hold
65
– – ﹤0.01% 1031
2021
Q2 		$3K Hold
65
– – ﹤0.01% 1006
2021
Q1 		$3K Hold
65
– – ﹤0.01% 973
2020
Q4 		$3K Buy
+65
New +$2.2K ﹤0.01% 844

Other funds holding TGTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Evoke Wealth's TGTX Position: Q2 2022 in Review

Evoke Wealth sold out of TG Therapeutics (TGTX) in Q2 2022, closing a stake of 219 shares — an estimated $2K sold.

Evoke Wealth first reported a position in TGTX in Q4 2020 and held it in 6 quarters. The position peaked at $3K in Q2 2021. 174 funds tracked by Wall St. Rank hold TGTX as of Q2 2022.

  • Evoke Wealth reported no remaining TG Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Evoke Wealth sold 219 TG Therapeutics shares in Q2 2022, an estimated $2K.
  • Evoke Wealth first reported a position in TG Therapeutics in Q4 2020 and held it in 6 quarters.
  • Evoke Wealth's TG Therapeutics position peaked at $3K in Q2 2021.
  • 174 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2022.

Based on Evoke Wealth's 13F filing for Q2 2022, filed 4 Aug 2022.